版本:
中国

BRIEF-Janssen Research & Development submits supplemental application to FDA to update prescribing information for Xarelto

April 28 Johnson & Johnson-

* Janssen Research & Development says it has submitted supplemental new drug application to u.s. Fda to update prescribing information for xarelto

* Janssen seeks to update prescribing info for xarelto to add 10 mg dose to reduce patients' risk of recurrent venous thromboembolism Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐